Results 201 to 210 of about 30,536 (239)
Some of the next articles are maybe not open access.
2014
Besides 5-azacytidine (azacitidine, Vidaza®), 5-aza-2'-deoxycytidine (decitabine, Dacogen®) is the most widely used inhibitor of DNA methylation, which triggers demethylation leading to consecutive reactivation of epigenetically silenced tumor suppressor genes in vitro and in vivo.
Hackanson, Björn, Daskalakis, Michael
openaire +3 more sources
Besides 5-azacytidine (azacitidine, Vidaza®), 5-aza-2'-deoxycytidine (decitabine, Dacogen®) is the most widely used inhibitor of DNA methylation, which triggers demethylation leading to consecutive reactivation of epigenetically silenced tumor suppressor genes in vitro and in vivo.
Hackanson, Björn, Daskalakis, Michael
openaire +3 more sources
Low-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDS.
NEJM Evidence, 2022Decitabine and Azacitidine in MDSPreviously data in adults with low- or intermediate-risk MDS or CML randomized to receive either low-dose decitabine or low-dose azacytidine with follow-up of 20 months had been reported.
K. Sasaki +23 more
semanticscholar +1 more source
Current Opinion in Oncology, 2003
Decitabine is a cytosine analogue synthesized in the 1960s that is currently enjoying a revival of interest prompted by the elucidation of DNA methylation inhibition as its major mechanism of action, along with increased understanding of the role of DNA methylation in epigenetic dysregulation in cancer.
openaire +2 more sources
Decitabine is a cytosine analogue synthesized in the 1960s that is currently enjoying a revival of interest prompted by the elucidation of DNA methylation inhibition as its major mechanism of action, along with increased understanding of the role of DNA methylation in epigenetic dysregulation in cancer.
openaire +2 more sources
Blood
A metronomic, low-dose schedule of decitabine and venetoclax was safe and effective in myeloid malignancies with few dose reductions or interruptions in an older diverse population.
M. Goldfinger +26 more
semanticscholar +1 more source
A metronomic, low-dose schedule of decitabine and venetoclax was safe and effective in myeloid malignancies with few dose reductions or interruptions in an older diverse population.
M. Goldfinger +26 more
semanticscholar +1 more source
Oral decitabine plus cedazuridine versus intravenous decitabine
The Lancet HaematologyContains fulltext : 304917.pdf (Publisher’s version ) (Closed access)
openaire +3 more sources